{"id":"depakote-divalproate","safety":{"commonSideEffects":[{"rate":"25-50%","effect":"Tremor"},{"rate":"20-40%","effect":"Nausea"},{"rate":"15-30%","effect":"Sedation/somnolence"},{"rate":"10-20%","effect":"Weight gain"},{"rate":"5-15%","effect":"Alopecia (hair loss)"},{"rate":"1-5%","effect":"Thrombocytopenia"},{"rate":"<1%","effect":"Hepatotoxicity"},{"rate":"<1%","effect":"Pancreatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Divalproate (the sodium salt of valproic acid) works through multiple mechanisms: it increases GABA synthesis and reduces GABA catabolism, thereby enhancing inhibitory neurotransmission in the central nervous system. Additionally, it inhibits histone deacetylase enzymes, leading to increased histone acetylation and altered gene expression patterns. These combined effects stabilize neuronal membranes and reduce neuronal excitability.","oneSentence":"Divalproate increases brain GABA levels and inhibits histone deacetylase, enhancing inhibitory neurotransmission and altering gene expression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:32:20.948Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (seizure disorders)"},{"name":"Bipolar disorder (acute mania)"},{"name":"Migraine prophylaxis"}]},"trialDetails":[{"nctId":"NCT03914534","phase":"PHASE4","title":"Bioequivalence Study of Sodium Divalproate Tablets 500 mg","status":"COMPLETED","sponsor":"Tecnoquimicas","startDate":"2017-04-17","conditions":"Healthy","enrollment":30},{"nctId":"NCT02556320","phase":"NA","title":"Immunological and Viral Parameters in Patients Receiving Anti-epileptic Drugs","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2013-05","conditions":"Epilepsy, Drug Hypersensitivity Syndrome","enrollment":30},{"nctId":"NCT00271258","phase":"PHASE3","title":"Safety Study of Sodium Divalproate in Bipolar Disorder in Adolescents","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-01","conditions":"Bipolar Disorder","enrollment":200},{"nctId":"NCT00545675","phase":"PHASE4","title":"Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2007-12","conditions":"Bipolar Disorder","enrollment":146},{"nctId":"NCT00545142","phase":"PHASE4","title":"Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2007-10","conditions":"Bipolar Disorder","enrollment":280}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Depakote (divalproate)","genericName":"Depakote (divalproate)","companyName":"Korea Otsuka Pharmaceutical Co., Ltd.","companyId":"korea-otsuka-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Divalproate increases brain GABA levels and inhibits histone deacetylase, enhancing inhibitory neurotransmission and altering gene expression. Used for Epilepsy (seizure disorders), Bipolar disorder (acute mania), Migraine prophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}